



# Elrexio in UAE

*The MoHAP named-patient coordination pathway — indicative 2026*

ONCOLOGY · BCMAXCD3 BISPECIFIC MYELOMA

## The clinical situation

Elrexio (elranatamab) is a humanised BCMAXCD3 bispecific T-cell engager for heavily pre-treated relapsed/refractory multiple myeloma (typically after four prior lines including a PI, IMiD, and anti-CD38). Manufactured by Pfizer. Administration is subcutaneous on a step-up schedule (12, then 32 mg) followed by 76 mg weekly; the step-up phase requires inpatient CRS/ICANS monitoring. Hypogammaglobulinaemia and opportunistic-infection surveillance with IVIG supplementation are standard.

### The pathway, 5 steps

- 1 Consultation & clinical rationale.** Your treating haematologist documents prior-line sequence, performance status, and cytopenia/infection baseline.
- 2 Administering centre confirmed.** A UAE tertiary haematology unit with CRS/ICANS capability is nominated; step-up beds booked.
- 3 MoHAP named-patient application.** Clinical rationale, patient reference, centre-capability attestation, and dosing plan are filed.
- 4 US-side sourcing & logistics.** Reserve Meds coordinates product through our US-licensed DSCSA-compliant specialty wholesale partner under validated cold chain.
- 5 Step-up admission & ongoing therapy.** The tertiary centre admits for step-up, manages CRS/ICANS, transitions to weekly outpatient maintenance.

### Indicative economics

**Reference US cash-pay range:** USD 41,000–47,000 per month at 76 mg weekly maintenance (drug-only reference; Reserve Meds provides a transparent delivered quote at intake). Inpatient step-up admission is separate local cost.

### Indicative first-dose timing

**7–14 days** from a complete MoHAP application to first-dose step-up admission, once cohort intake opens.  
Indicative — not guaranteed.

## Reserve Meds's role

**Sourcing.** US-licensed specialty wholesale partner, DSCSA chain-of-custody. **Documentation.** Regulatory package for your physician and MoHAP review, keyed to the BCMA-bispecific rationale. **Logistics.** Validated cold-chain shipment to the nominated tertiary centre. **Concierge case lead.** Named point of contact through step-up and maintenance cadence. **We are a coordinator** — not the prescriber, not the dispensing pharmacy. All clinical decisions remain with your treating haematologist and administering centre.

**COMPOSITE EXAMPLE · PRE-LAUNCH WAITLIST**

**Join the Elrexio × UAE first-cohort waitlist.** *Our concierge reaches out as we open intake.*

[reservemed.com/access-guides/elrexio-uae.html](https://reservemed.com/access-guides/elrexio-uae.html)



SCAN TO JOIN

**Reserve Meds** · US-based concierge for cross-border specialty medicine. We are a coordinator; we are not the prescriber and not the dispensing pharmacy. All clinical decisions remain with the treating physician. Not medical advice.

*Reserve Meds is in pre-launch. Service availability is limited to our first cohort; all timelines published are indicative, not guarantees. Composite case examples only.*

**reservemed.com** · [hello@reservemed.com](mailto:hello@reservemed.com) · WhatsApp concierge: +1 516 528 3120 · Reviewed 2026-04-23 by Reserve Meds clinical & regulatory team